Company intelligence / Profile preview
Genovate Biotechnology
Hsinchu City, Hsinchu, Taiwangenovate-bio.com ↗
- Ownership
- Private
- Employees
- ~195
- Development stage
- Other
01
Overview
Genovate has a strong track record of developing new formulations of small molecule drugs, especially branded generics and controlled-release products. Its lead asset PMR (extended-release cilostazol) achieved primary endpoints in a pivotal bioequivalence trial supporting an upcoming NDA filing with the US FDA. The company also markets a broad portfolio of generic and specialty pharmaceuticals across multiple therapeutic areas.
- Therapeutic areas
- GastroenterologyEndocrinologyOncologyImmunologyCardiovascular
- Modalities
- Small moleculeBranded genericsControlled-release dosage forms
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Beyond the preview
Go deeper on Genovate Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Genovate Biotechnology.